Update on Scheduled FDA Advisory Committee Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
Mesoblast (MESO) Receives Backing from FDA Panel for Remestemcel-L
August 13, 2020 5:05 PM UTCMesoblast (NASDAQ: MESO) Receives Backing from FDA Panel for Remestemcel-L
FDA ADCOMM VOTE: Do the available data support the efficacy of remestemcel-L in pediatric patients with steroid-refractory aGVHD?
8-Yes
2-No
0-Abstain
aGVHD = acute graft-versus-host disease$MESO #Ryoncil #MesenchymalStromalCells #StemCellTherapy
... More
Despite Concerns, Cantor Fitzgerald Thinks Mesoblast's (MESO) Ryoncil Could Be Approved
August 11, 2020 8:19 AM UTCCantor Fitzgerald analyst Louis Chen weighed in on Mesoblast Limited (NASDAQ: MESO) after shares were slammed 25%+ following FDA briefing documents that raised the "Fear Factor" about Ryoncil, in the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in children. Chen thinks Ryoncil could be approved despite the fears.
The FDA AdCom for MESO's Ryoncil is on 8/13 from 8am to 5pm ET. The FDA's Oncologic Drugs... More
